Govt supports commercialisation of indigenous AI-powered cervical cancer screening technology

image credit- pib

The Technology Development Board (TDB) of the Department of Science and Technology (DST), Government of India, has entered into an agreement with Griva Healthcare in Visakhapatnam. The agreement will support the manufacture and commercialisation of an indigenously developed, Artificial Intelligence (AI)-enabled portable digital colposcope 'GrivaVision'. 'Cervivision' helps in early detection of lesions before they become cancerous in the cervix.

In collaboration with TDB, the company will set up manufacturing capacity in Kollam, Kerala, enabling extensive production and use of the technology on a commercial scale.

This initiative aims to make cervical cancer screening more accessible and affordable, especially in primary and community healthcare centers. Simultaneously, it will help strengthen domestic capabilities in advanced medical devices and reduce dependence on imported diagnostic equipment.

GrivaVision is a portable diagnostic platform that integrates a high-definition camera, in-built display, user-friendly interface, advanced optics, and indigenous AI-enabled software. Designed for visualization of the vaginal passage and the examination of cervical lesions, the system assists gynecologists in identifying pre-cancerous abnormalities during routine diagnostic check-ups.

The technology is designed according to the Automated Visual Assessment (AVE) standards approved by the World Health Organization (WHO) and its software is ABDM compliant, enabling its integration with India's evolving digital health ecosystem.

The product is a category B non-invasive medical device and is licensed to manufacture CDSCO category B. It is being developed to ISO 13485 quality standards. The hardware architecture is the company's own specialty and is patented by Griva Healthcare in India. The company is currently engaged in R&D work at AIC-AMTZ Medivalley, Visakhapatnam, and will help it move towards commercial production at the upcoming facility to be set up in Kerala under the TDB supported project.

The technology has been developed and manufactured in India, and more than 50% of its product components are currently indigenously sourced. Large-scale commercialisation is expected to further strengthen the home medical device value chain and create a cost-effective Indian option in cervical cancer diagnosis.